Related Experiment Videos
Malignant mixed mesodermal tumors of the ovary
P A DiSilvestro1, W H Gajewski, M E Ludwig
1Women & Infants Hospital/Brown University, Providence, Rhode Island, USA.
Obstetrics and Gynecology
|November 1, 1995
Summary
Malignant mixed mesodermal tumors of the ovary have a poor prognosis, with a median survival of 7 months and high mortality rates within one year. Further research is crucial for improved management strategies.
Area of Science:
- Gynecologic Oncology
- Pathology
- Clinical Medicine
Background:
- Malignant mixed mesodermal tumors (MMMTs) of the ovary are rare and aggressive neoplasms.
- These tumors present significant challenges in diagnosis and treatment, often leading to poor patient outcomes.
Purpose of the Study:
- To review the clinical experience with ovarian MMMTs at Women & Infants Hospital and Hartford Hospital.
- To analyze survival rates and treatment outcomes for these rare malignancies.
- To compare institutional findings with existing literature data.
Main Methods:
- A retrospective review of 14 cases of ovarian MMMTs diagnosed over a 5-year period at two hospitals.
- Data collection included patient demographics, tumor pathology, treatment modalities, and survival status.
- Literature review of published studies on ovarian MMMTs to contextualize findings.
Main Results:
- The median survival for patients in this series was 7 months.
- Sixty-four percent of patients died of disease within one year of diagnosis.
- Literature review indicated similar poor outcomes, with median survivals of 6-12 months and over 70% mortality at one year, despite treatment.
Conclusions:
- Current management strategies for ovarian MMMTs have significant limitations, leading to dismal survival rates.
- Further research is imperative to identify more effective therapeutic approaches.
- Clinical management should prioritize maintaining quality of life due to the limited efficacy of current treatments.